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Objective: To evaluate the feasibility of the transperineal implementation of biocompatible balloon (Prospace) and
the acute toxicity of high dose 3DCRT in patients with localized low risk prostate cancer.
Materials and methods: Between December 2011 and April 2012, fifteen patients were treated with external
3DCRT consisted of 76–78 Gy in 38–39 daily fractions (2.0 Gy/ fraction). Before 3DCRT, we placed the Prospace
though the perineum by a minimally invasive procedure in the intermediate space between the rectum and the
prostate. The primary study endpoint was the evaluation of acute toxicity according to the EORTC/RTOG radiation
toxicity scale. Erectile function was evaluated with the IIEF-5 questionnaire. Rectosigmoidoscopy was performed at
baseline, at the end of 3DCRT and 3 months thereafter in order to assess also the rectal toxicity according to
Subjective-RectoSigmoid (S-RS) scale. The evaluation of pain related to Prospace implementation was done with the
visual analogue score (VAS).
Results: The acute toxicities were as follows: grade I GI toxicity in two patients and for GU toxicity, three patients
with grade I of nocturia, four patients with grade I of frequency, two patients with grade I and two patients with
grade II of dysouria. The mean score of rectal toxicity according to S-RS score was 1.8(±0.6). The mean VAS score
related to Prospace was 1.4(±0.5). Erectile function was unchanged. The Prospace device was found stable in
sequential CTs during irradiation.
Conclusions: The implementation of PROSPACE was feasible, while the acute radiation toxicity was low and
comparable with IMRT techniques.
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Table 1 Patients’ characteristics
Median age (range) 71 (65–77)
Mean initial PSA (range) 9.1±0.7 ng/ml (7.2-9.8)
T1 3/15
T2 12/15
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Prostate cancer is the most commonly diagnosed neo-
plasia found in older men, in western world [1]. It repre-
sents the second leading cause of oncologic deaths in
American men. About one in 20 prostate cancer deaths
occur in men ages 55–64, 2 in 10 deaths occur in men
ages 65–74 and 7 in 10 prostate cancer deaths occur in
men ages 75 and older [2]. One of the standard curative
treatments for low risk disease is a radical course of ra-
diation therapy. Radiation therapy is a recognized treat-
ment for PC and high-dose 3DCRTis the recommended
standard of care for localized tumours [3].
There is definitely a relationship between dose escal-
ation and response to radiation treatment with radiation
induced morbidity to normal surrounding tissues [4,5].
Intensity modulated radiotherapy improves the treat-
ment outcome, sparing the normal surrounding tissues
and reducing the acute and late radiation induced tox-
icity [6-8]. The total dose of radiotherapy that can be
delivered through conventional conformal techniques
is still limited by the tolerance of surrounding normal
tissues, mainly the rectum and the bladder [9].
Levy et al. have already reported on a new balloon made
of a biodegradable polymer called ProspaceW consisted of
poly(lactide-co-epsilon-caprolactone) [10]. Balloon's mech-
anical and chemical properties were nicely documented
both in vitro and in vivo. Prospace was safe and effective
for its intended use of separating prostate from the rec-
tum for a desired duration in experimental models [11].
A clinical study was in need to evaluate the safety and
efficacy of this device during irradiation in patients with
prostate cancer.
Thus, the aim of this study was to evaluate the feasibility
of implanted biocompatible balloon as well as the acute
GI and GU toxicity for localized low risk prostate cancer
patients (cT1-2 N0) undergone high dose radiotherapy.
The primary endpoints of this prospective phase II study
were the assessment of pain or discomfort related to
implementation as well as the monitoring of acute GI
and GU radiation induced toxicity. The secondary end-
points were the monitoring of PSA values post irradi-




In a retrospective way, clinical data of 15 patients treated at
University Hospital of Athens, Attikon between December
2011 and April 2012, were collected. The pretreatment
evaluation included medical history, physical examination,
blood profile (including Complete Blood Count, PSA de-
termination, liver function tests, testosterone measure-
ment) and staging exams as CT and MRI of the pelvis.
The patient characteristics are summarized in Table 1.All patients had good performance status according to
Eastern Cooperative Oncology Group performance score
of 0–1. Median follow-up duration was 6 months (range,
3–9 months).
Inclusion criteria
Eligible patients had histologically confirmed clinical Pros-
tate Cancer Stage T1-2 (according to American Joint Com-
mittee on Cancer staging manual, 7th edition, 2010),
Gleason score < 7 and prostate-specific antigen (PSA)
levels less than 10 ng/mL. All patients had to be medically
inoperable for radical prostatectomy due to co-morbidities
(cardiac surgery or stent after cardiac mal-function, chronic
obstructive lung disease, etc.).
Exclusion criteria
Patients were ineligible if they had undergone previous
pelvic RT, neoadjuvant androgen ablative therapy or
radical prostatectomy, lymph node metastatic involve-
ment, distant metastases or had a hip prosthesis.
Balloon implementation
All patients underwent an implementation of Prospace
though the perineum. The Prospace Balloon implantation
was performed in an outpatient basis under local anesthesia.
Prior to the implantation procedure each patient was
examined with urine culture to ensure that he has no
urine infection, and also was checked for coagulation
disorders and stopped any anticoagulant therapy 5 days
prior to the implantation date and was replaced with
low molecular weight heparin.
The morning of the procedure the patient was adminis-
tered a per-os antibiotic, preferably such as a fluroquinolone,
together with a rectum enema. The Prospace Balloon
system packaging consists of a biodegradable inflatable
balloon mounted on a deployer, and a balloon delivery
echogenic kit consisting of a needle, a dilator and an
introducer sheath. The balloon material was a co-polymer
of poly lactide acid and epsilon caprolactone which was
designed to degrade in situ after 3–6 months from place-
ment. Also a syringe was required to perform skin and fascia
anesthesia and to inflate the balloon with warm saline.
Placement of the balloon was performed under local
anesthesia and continuous TRUS guidance. The patient
was placed in lithotomy position and the perineum was
scrubbed in a standard manner, while a urethral catheter
was inserted and kept in place during the whole procedure.
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inserted in patient’s rectum and kept in place through-
out the whole procedure (Figure 1). Local anesthesia of
the perineum was performed by an anesthetic solution
injected in the midline approximately 1.5cm above the
anal verge. After local anesthesia of the perineum skin
and underlying fascia has been achieved, the needle of
the delivery kit was inserted in the same location of the
local anesthesia and was advanced until the prostate
apex under continuous TRUS guidance. From this point,
we continue to advance the needle while making hydro
dissection with the anesthetic solution, until the needle
reaches the prostate base. The hydro dissection with the
anesthetic solution produces local anesthesia but also
facilitates the separation of the space between the rec-
tum and the prostate and will enable smoother entry
and advancement of the introducer sheath later in the
procedure. When the needle reaches the correct pos-
ition, verified by the TRUS, we made a perineal skin and
fascia incision, 0,5cm high and 1cm deep around the
needle access point. The incision was done to allow
room for the dilator and the introducer sheath to be
inserted freely into the perineum. Next, while holding
the needle in place we advanced the dilator, coupled
with the introducer sheath, over the needle towards the
prostate base until the designated mark on the needle
appears. At this point the dilator tip was aligned with
the needle tip and while holding firmly the dilator and
introducer sheath in place, we remove the needle. Then,
while holding the dilator in place, we continue toFigure 1 Transrectal ultrasound visualization of the prostate
during the balloon implantation procedure.advance the sheath over the dilator until the sheath
reaches the prostate base as viewed by the TRUS. After
verifying the correct position of the sheath in the mid-
line by TRUS, we holded firmly in place the introducer
sheath and removed the dilator leaving the introducer
sheath in place. Now the introducer sheath acted as a
working channel through which the balloon would be
introduced. To introduce the balloon, we holded the
introducer sheath firmly and we insured that the bal-
loon deployer centering strip was facing upwards while
advancing the balloon through the introducer sheath
until the mark on the deployer reaches the introducer’s
sheath proximal end (Figure 2). Then to withdraw the
introducer sheath we holded the balloon deployer firmly
and we pulled the introducer sheath all the way back. At
this point the balloon was fully exposed in situ and
ready for deployment. Once again we verified by TRUS
that the balloon was correctly positioned in the midline.
We slowly started to fill the balloon with warm saline
under continuous TRUS visualization, in order to ensure
that during the inflation of the balloon the rectal wall
remained at least 3mm thick. The volume of the saline
inflated into the balloon, was unique for each balloon,
and marked on the package of the balloon, but usually
was between 14cc to 17 cc of normal saline. Once the
balloon was fully inflated with the designated amount of
saline, we detached and sealed the balloon in place by
firmly retracting the inflation syringe from the deployer.
Now the balloon was firmly positioned in place between
rectum and prostate and we could remove safely theFigure 2 Placement of the introducer sheath under
ultrasound guidance.
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performed a final check of the balloon position by the
TRUS as well as by palpation of the rectum to ensure
not only that the balloon was in the correct place but
also to ensure the integrity of the rectal mucosa. Finally
we sutured the perineum incision, if required, and we
removed the urethral catheter. The patient was dismissed
from the hospital the same day, as soon as he urinates,
and was given oral antibiotics for 3–5 days.
The clinical use of PROSPACE was recently approved
by the Central Board of Health of the Greek Ministry of
Health. Beyond this, all patients signed informed con-
sent about the use of Prospace.
The evaluation of pain or discomfort related to the
Prospace implementation was done with the visual
analogue score (VAS) [12]. The erectile function was
evaluated with the International Index of Erectile Func-
tion (IIEF-5) [13].
Radiotherapy technique
Each patient underwent a virtual CT-simulation, in
supine position, using “knee sponge” to consistently align
thighs [14,15]. Patients are instructed to have a full blad-
der and empty rectum (following a dietary suggestion)
during simulation and the whole course of treatment.
For treatment planning, a CT scan covering a region
from the first lumbar vertebra to the lower part of the
perineum was obtained for each patient. A conventional
virtual CT simulation before CT scan was performed to
define preliminary isocenter and beam width.
All contouring of target volumes and normal structures
(organs at risk-OARs) were performed in the Prosoma
Treatment Planning System. Magnetic resonance and
computed tomography images were obtained at 3-mm
intervals. The CT and MRI were registered by the Pro-
soma system while corrections were made in the CT-
based contouring of the prostate by taking into account
the MRI images. CT and MRI images were obtained
nearly 4 weeks after balloon implementation in order
to avoid the post-implantation oedema. The following
structures were delineated: CTV, PTV according to the
ICRU criteria [15-17].
The CTV was the prostatic gland; the PTV was obtained
by expanding CTV with a margin of 1 cm in each direc-
tion, and of 0.7 cm posteriorly [18]. The CTV, PTV and
OARs were outlined on all CT slices [19-21]. No patients
received pelvic node or seminal vesicles irradiation.
The prescription dose of 76–78 Gy was defined for
the 95% isodoses of the PTV. Beams were conformally
shaped around the PTV and partial wedging or dynamic
Multi Leaf Collimator (MLC) was employed to improve
dose homogeneity. To evaluate the dose constraints
for normal tissues we used the NCCN 2010 guidelines
(www.nccn.org), the Radiation Oncology Group (RTOG)GU consensus as reported by Lawton et al. and the
QUANTEC report [22,23].
The dose constraints for the OARs are described below:
1. Bladder: V75 <25%, V70 <35%, V65 <50%.
2. Rectum: V75 <15%, V70 <20%, V65 <25%, V60 <35%,
V50 <50%.
3. Femoral heads: V50 <5%.
4. Small bowel: V52 = 0%.
5. Penile bulb: Mean dose <50 Gy.
The PTV was treated, using a four field technique
[24,25]. The total prescribed dose was 76–78 Gy, deliv-
ered in 38–39 daily fractions (Monday to Friday) to the
whole prostatic gland, given in 2 Gy fractions. Treat-
ments were delivered with 15 MV photon beam gener-
ated by a Clinac 2100 C Varian accelerator. A typical
dose distribution together with a DVH in a patient after
the balloon implemented is shown in Figure 3a, while
the dose distribution and the DVH in the same patient
before the balloon implementation are shown in Figure 3b.
For the evaluation of stability of Prospace after imple-
mentation we used a non-rigid registration technique
implemented in four sequential CT scans of the patients
during radiotherapy schedule [26].Clinical examination
During the radiation treatment the patients were moni-
tored every week with clinical examination. After the com-
pletion of the treatment, the patients were evaluated by
a radiation oncologist every month for a three months
period of time. GU and GI toxicity were defined according
to the RTOG/EORTC acute radiation morbidity scoring
system [27]. The rectal toxicity was also assessed with the
Subgective-Rectosigmoid Scale using a modified toxicity
scale based on LENT-SOMA grading scale [28,29]. The
modification took into account the initial LENT-SOMA
scale (LENT SOMA tables, 1995), focused on endpoints
for acute rectal mucositis together with the scoring sys-
tem based on the endoscopic terminology of the World
Organization for Digestive Endoscopy, as published by
the ESGE (European Society for Gastrointestinal Endos-
copy) [30,31]. The objective measurements were coming
from flexible rectosigmoidoscopy performed at baseline,
1–2 days after the completion of radiotherapy schedule
and three months thereafter. The final score was the
sum of scores of the 8 items (score=0, if there were
no toxicities).
Data at diagnosis (baseline), end of radiation treatment
and at all monthly follow up visits, 90 days after finishing
radiotherapy have been analyzed in this report. Symptoms
occurring in the interval between the start of radiotherapy
and 90 days after this time point were classified as “acute”.
Figure 3 CT plane with isodose distribution. The Prospace is outlined in white (arrow). 3a: with balloon; 3b: without balloon.
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The comparison for PSA values and toxicity levels in
terms of paired mean-value statistics, was done with the
Wilcoxon non-parametric test. The significance level
was set at the level of 0.05. All the statistical test and the
descriptive statistics were performed with the SPSS ver
10 software (IL, USA).Table 2 EORTC/RTOG GI and GU acute radiation induced toxi
Grade 0 Grade I
EORTC-RTOG scale for
lower Gastro-intestinal
None Increased frequency or chang
of bowel habits not requiring












The median follow-up was 6 months. Treatment compli-
ance was excellent. As shown in Figure 3, the D50 for the
rectum in terms of a DVH in an irradiated patient was
dramatically decreased from 52Gy to 36Gy. According to
EORTC/RTOG scale, as shown in Table 2, the acute toxic-





Diarrhea requiring parasympatholytic drugs/mucous
discharge not necessitating sanitary pads/ rectal or
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with grade I of frequency, two patients with grade I and
two patients with grade II of dysouria. The mean score of
rectal toxicity according to S-RS score was 1.8 (SD±0.6);
only grade I toxicity was noted. The results in details
concerning the S-RS score are shown in Table 3.
The implementation of Prospace was feasible. Neither
any serious morbidity for the patient nor any difficulty
for the urologist who implemented the device was noted.
The mean VAS score related to Prospace implementa-
tion was minimal at the level of 1.4 (SD±0.5). Some of
the patients complained only for a mild discomfort for
24 hours after the implementation.
Acute toxicity was minimal after patients finished RT;
at 3 months of follow up, no patient had any GI toxicity
score, while two patients remained with grade I GU tox-
icity (dysouria). The decrease of mean score of EORTC/
RTOG acute toxicity at three months compared to the
score noted during irradiation was significant (P<0.01,
Wilcoxon test). In terms of SRS score, two patients
remained with only rectosigmoid findings of grade I
toxicity (localized-spotted congested mucosa), showing
also a significant reduction compared to the score
noted at the completion or RT (P<0.01, Wilcoxon test).
As presented in Table 4, the IIEF−5 measurements at
baseline and three months thereafter showed no sig-
nificant differences (P=0.157, Wilxocon test).
The PSA levels in all cases post irradiation were
lower than 1.4ng/ml, with a mean value of 0.44 ±0.47.Table 3 Rectal toxicity according to S-RS grading scale at









Stool frequency 2-4 per day
5/15





Mucosa-surface Localized-spotted congested mucosa
3/15
Ulceration Superficial 1 cm2
1/15
Only Grade I acute toxicity was noted.The baseline and post-RT PSA values are presented
in Table 4, showing a significant reduction (P<0.01,
Wilcoxon test).
Treatment was administered only in cases of GU tox-
icity: non-steroid anti-inflammatory for dysuria, urgency,
frequency, nocturia.
For the registration we used as stable the referential
skin markers and the isocenter point. The balloon sur-
face was outlined in CT and its anatomical position was
monitored assessing any geographical displacement. The
non-rigid registration in sequential CT scans of the pel-
vis revealed the stability of the Prospace devise, showing
displacements only at 3mm maximum.
Discussion
According to the literature, there is a significant correl-
ation of dose escalation and response to treatment for
prostate carcinoma [4,5,8,9]. High dose of conventional
fractionated radiation schedules or hypofractionation
schemes and associated higher rectal doses have evoked
the need for improved protection of the rectum during
prostate cancer irradiation [7,9]. Radiotherapy side ef-
fects include rectal irritation and bleeding, erectile dys-
function and urinary frequency. Since in conformal
radiotherapy, irradiation isodose distribution includes a
part of the rectum, displacing irradiated prostate away
from anal and rectum, would reduce damage and there-
fore side effects.
Levy et al. reported on Prospace as an implantable,
biodegradable, inflatable, preshaped triangular balloon
of commercially used poly(L-lactide-co-epsilon-caprolactone)
co-polymer material to provide separation between pros-
tate and rectum [10]. Biocompatibility and degradability
of the Prospace in conjunction with local irradiation
were evaluated in several in vivo studies [11]. The device
was found to be biocompatible in subcutaneously im-
planted rabbits up to 42 days, in a transperineally im-
planted dog, up to 12 months and in 8 transperineally
implanted pigs, up to 6 months. Since the balloon has
been inflated, it remained stable for several months and
subsequently the tissues remained separated. In experi-
mental animals, histopathology has shown no systemic
or local toxicity. After three months post irradiation
evaluation, in pigs that received 15 Gy (3 fractions once
per week) the investigators documented the stability of
the balloon position without any local or systemic side
effects. They also reported that the balloon's prepar-
ation ensures no bonding across anatomical interfaces
by means of mechanical stability during implantation.
In our case the non-rigid registration techniques with
sequential CT scans of the pelvis showed also stability of
the device [15]. Most studies reported an advantage for
IMRT in GI toxicity, attributed to increased conformality
of treatment compared with 3DCRT, particularly with
Table 4 VAS score related to Balloon implementation, S-RS score with subjective and objective findings











Baseline PSA Post RT PSA
1 2 2 0 23 22 8.7 0.3
2 1 2 0 22 23 9.8 0.2
3 2 2 0 22 21 9.1 0.2
4 1 3 1 23 22 9.7 0.1
5 2 1 0 22 22 9.5 0.01
6 1 2 0 22 22 9.6 0.4
7 1 2 0 20 20 7.2 0.1
8 2 2 0 21 22 9.4 0.1
9 1 2 1 22 21 8.7 0.1
10 1 1 0 21 21 8.9 0.01
11 2 1 0 20 20 9.0 1.2
12 1 1 1 20 20 9.6 1.1
13 1 2 1 21 20 8.7 0.9
14 1 2 0 21 20 8.5 0.5
15 2 2 0 23 23 9.8 1.4
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there was some indication that genitourinary toxicity
was worse for patients treated with dose escalated IMRT
techniques, although most studies did not find a signifi-
cant treatment effect [3]. In our study the GI toxicity
was minimal and equivalent to IMRT techniques, while
the GU toxicity was slightly worse in accordance with
the reported urinary toxicity from IMRT trials. However
we have to emphasize that the technique used was con-
ventional 3D conformal and not IMRT, by means of the
sparing of the rectum only due to distance achieved
from the irradiated area and definitely of the inability of
bladder sparing. Although IMRT is the standard tech-
nique for prostate irradiation in many RT departments,
the balloon implementation would offer a safe dose
escalation, in terms of further decreasing mainly the
potential rectal toxicity.
Livi L et al. reviewed 100 patients with localized pros-
tate cancer, receiving 80 Gy with a biphasic technique
(3DCRT + IMRT) [32]. The median follow-up time was
12 months, while 18% developed acute Grade 2 rectal
toxicity, and no patient experienced acute grade 3 or
higher rectal symptoms. Acute Grade 2 urinary symptoms
were observed in 44% of the patients. Ruy et al. in another
trial with 173 patients reported the toxicity on a 3D-CRT
trial for prostate carcinoma with a prescription dose of
79.2Gy [33]. The grade III acute toxicity for bladder or
bowel was less than 3%, while 54% of patient presented
no or grade I toxicity. Michalski in another study, showed
remarkably low grade III toxicity (4%), for patients who
received 78Gy at the prostatic gland [34]. Ghadjar et al.
reported on 102 patients with 80 Gy prescribed dose,delivered with IMRT technique [35]. The study showed
2% grade II GI toxicity and 43% of less than grade III
GU toxicity. Mantzinger et al. in EORTC22991 trial
with either 3D-CRT or IMRT for intermediate or high
risk prostate cancer, reported 0.8% and 6.3% of grade III
GI and GU toxicity, respectively [36]. Al-Mamgani et al.
reported a significant lower incidence of acute grade II
or higher GI toxicity when IMRT was used instead of
3D-CRT (20% vs 61%, respectively), while no significant
difference was noted for GU toxicity between the two
techniques [37]. Deville et al. [38] with the use of image-
guided intensity modulated radiation therapy for prostate
cancer using a daily water-filled endorectal balloon for
immobilization, reported maximum GI toxicity of grade 1
and 2 up to 23% and 8%, respectively. In our study the rate
of acute toxicity was remarkably low. The reason for this
should be the use of Prospace, concerning the GI toxicity
and the small field used for the irradiation of the prostatic
gland only concerning the GU toxicity (no pelvic fields
used). The IIEF−5 questionnaire showed no impact to
erectile function related either to Prospace or to radiother-
apy, although the position of the balloon was at the
anatomical cite of the neurovascular bundle. This fact
further indicates the safety of the balloon implementa-
tion. However, in our study the number of patients is
really low, making the extraction of safe conclusions
impossible, even for the evaluation of acute toxicity.
Thus we have to emphasize on the implementation method
used rather than on the radiation induced morbidity. More-
over, we have to underline the need of a longer follow up,
in order to further evaluate the late rectal and urinary
radiation induced toxicity.
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biochemical and distant failures after external beam radio-
therapy for prostate cancer [39]. Although in our study
the follow-up was short, the PSA nadir was obviously
achieved as shown in Table 4, meaning that the response
to irradiation was excellent. In any case this should be
confirmed with more patients and extended follow-up.
At last but not least, we have the impression that the
balloon would be appropriate also for interstitial brachy-
therapy as monotherapy for the prostate cancer [40]. This
would have a potential clinical impact in terms of the po-
tential elimination of the already minimum acute rectal
toxicity related to brachytherapy. However, concerning the
deviation of US, there must be a correction for the filling
of the balloon since the content is water and consequently
should be different from the surrounding soft tissues.
Moreover, there are publications using HDR brachyther-
apy as boost after external beam RT, reporting a prescrip-
tion dose of 40-50Gy for the external beam [41-43]. From
our point of view, concerning the brachytherapy boost,
our technique would allow the escalation of the dose up
to 60Gy for the external beam, but this would need a dosi-
metric study with more patients.
In conclusion, the Prospace implementation is feasible
and the radiation induced toxicity especially for the rec-
tum is minimal, equivalent to IMRT techniques. More
patients are needed for the confirmation of the results of
the present study, which is on-going.
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